


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**Claim 1. (currently amended):** A method for treating beta-thalassaemia, comprising administering to a subject in need of treatment an effective amount of angelicin, represented by formula (1):



or a structural analogue thereof,

wherein the structural analogue is selected from the group consisting of optionally substituted linear and angular coumarins, optionally substituted heteroanalogues of angelicin, thiopyrano-benzofurans, acylangelicins, alkylangelicins, alkoxycarbamoylangelicins, and optionally substituted psoralens and isopsoralens.

**Claim 2. (canceled).**

**Claim 3. (withdrawn/currently amended):** The method according to claim 21, wherein the structural analogue is bergapten.

**Claim 4. (withdrawn):** The method according to claim 1, wherein the angelicin or structural analogue is in combination with at least one further modifier of the transcription process.

**Claim 5. (withdrawn):** The method according to Claim 4 in which the further modifier of the transcription process is selected from the group consisting of cytosine arabinoside, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine triphosphate (GTP), guanosine diphosphate (GDP) and guanosine monophosphate (GMP).